TICKERNERD
Menu
INMBINMBHealthcare · Biotechnology

INMB Stock Forecast: INmune Bio, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$1.46
−5.19% on the day

The 2 Wall Street analysts covering INmune Bio, Inc. hold a median 12-month price target of $8 — +447.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 24 Oct 2026 — in the upper half.

Market cap
$40.5M
Ticker Nerd rank
52/ 100
Median analyst target
$8.00
Analysts covering
2
Revenue$0.0
Operating income−$1.5M
Net income−$1.3M
Free cash flow−$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.0%
1M
−27.0%
YTD
−6.4%
1Y
−18.4%
From 52W high
−41.8%
From 52W low
+30.4%
$1.12
$2.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INMB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores INmune Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Oct 2026
52/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Size
82
Revisions
66
Momentum
48
Accruals
46
Value
41
Volatility
38
Quality
33
Issuance
19

Growth (86): Sales and profits are climbing, and climbing faster than before.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INMB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INMB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26INMBHigh $9.00Median $8.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $4.00Median $8.00High $9.00

The green dot is the last close — the median target sits +447.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Mar 2026LUCID CAPITAL MARKETSUpgradeBuy$2.00 → $9.00
2 July 2025Maxim GroupMaintainsBuy—
1 July 2025BTIGDowngradeNeutral—
1 July 2025ScotiabankDowngradeSector Underperform—
13 Feb 2025Maxim GroupMaintainsBuy—
11 Feb 2025ScotiabankMaintainsSector Outperform—
21 Oct 2024Alliance Global PartnersInitiatesBuy$20
27 Sept 2024Raymond JamesInitiatesOutperform$18
22 Aug 2024ScotiabankInitiatesSector Outperform$22
1 June 2023BairdInitiatesOutperform—
24 May 2022B. Riley SecuritiesDowngradeNeutral—
24 May 2022BTIGMaintainsBuy—
24 Jan 2022B. Riley SecuritiesMaintainsBuy—
21 Apr 2021B. Riley FBRInitiatesBuy—
21 Apr 2021B. Riley SecuritiesInitiatesBuy—
25 Nov 2020BTIGInitiatesBuy—
25 Nov 2020H.C. WainwrightReiteratesBuy—
25 Nov 2020HC Wainwright & Co.MaintainsBuy—
25 Nov 2020Maxim GroupInitiatesBuy—
25 Nov 2020Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

INMB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

INMB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, INmune Bio, Inc. returned −18.4% against +14.3% for the S&P 500, dividends included.

INMB vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26INMBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INMB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

INmune Bio, Inc. (INMB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 82% of US stocks

Price / sales
810.4×

Cheaper than 1% of US stocks

Price / book
2.0×

Cheaper than 43% of US stocks

EV / EBITDA
−1.6×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−61738.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−74.8%

Higher than 17% of US stocks

Return on assets
−39.1%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

INmune Bio, Inc. (INMB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • INmune Bio, Inc. has a market value of $40.5M and an enterprise value of $23.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$18.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$15.7M.

  • Shares outstanding: 27.7M.

  • Trailing P/E: −0.8×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • INmune Bio, Inc. employs 21 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 26 Oct 2026

Data provided by Twelve Data

Peers

INMB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INMBINmune Bio, Inc.$40.5M52
ALDXAldeyra Therapeutics, Inc.$39.2M39
KLRSKalaris Therapeutics, Inc.$39.2M20
ACETAdicet Bio, Inc.$38.2M37
VERUVeru, Inc.$38.2M56
DWTXDogwood Therapeutics, Inc.$38.1M39
TILInstil Bio, Inc.$39.6M38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own INmune Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INMB news & analysis

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

GlobeNewsWire · 21 Oct 2026positive

INmune Bio submitted its final pre-Marketing Authorisation Application package to the UK MHRA for investigational RDEB therapy Ebstrocel. The company said faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027 subject to MHRA review.

Why it matters — The update outlines the company’s expected UK regulatory timeline for Ebstrocel, a late-stage investigational cell therapy for RDEB.

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

GlobeNewsWire · 21 Oct 2026positive

INmune Bio entered a Master Services Agreement with Uniphar Durbin Ireland to establish a framework for international access, distribution and commercialization of Ebstrocel, its therapy for RDEB. Initial efforts will focus on named-patient access in selected European and MENA markets.

Why it matters — The agreement creates a stated foundation for Ebstrocel’s international access and potential broader commercialization.

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

PRNewsWire · 14 Oct 2026positive

INmune Bio and Quantum Computing Inc. are collaborating to apply QCi’s Dirac-3S quantum optimization machine and AI to INmune Bio’s clinical research. The effort will seek potential new treatment indications and biomarkers for XPro.

Why it matters — The collaboration may help INmune Bio explore additional applications for XPro and marks QCi’s first commercial customer in pharmaceutical and biotechnology markets.

INmune Bio to Attend the 2026 Maxim Growth Summit

GlobeNewsWire · 6 Oct 2026neutral

INmune Bio announced that it will participate in the 2026 Maxim Growth Summit, scheduled for October 12–14 at The Hard Rock Hotel NYC.

Why it matters — INMB watchers may note the company’s participation in an upcoming industry summit.

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

GlobeNewsWire · 14 Sept 2026positive

INmune Bio announced the appointment of a Sanofi rare-disease executive and a biopharma business development leader to its board. The appointments are intended to strengthen the company's rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel advances toward potential commercialization.

Why it matters — The new board members bring expertise in rare-disease commercialization and business development, which could support INmune Bio's preparations as Ebstrocel moves closer to potential commercialization.

FAQ

Frequently asked questions about INMB stock

What is the INMB stock price forecast for 2026-2027?

The 2 Wall Street analysts covering INmune Bio, Inc. have a median 12-month price target of $8, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INMB stock a buy right now?

Of the 2 analysts covering INmune Bio, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks INmune Bio, Inc. 52 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INMB?

As at 24 Oct 2026, INmune Bio, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will INMB stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +447.9% from the last close, and Ticker Nerd's factor model ranks INmune Bio, Inc. 52 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INMB stock forecast for 2030?

No analyst covering INmune Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has INMB stock performed over the past year?

INmune Bio, Inc. returned -18.4% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does INmune Bio, Inc. do?

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases.

What is the latest news on INMB?

The most recent item we track (GlobeNewsWire, 21 Oct 2026): "INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027". INmune Bio submitted its final pre-Marketing Authorisation Application package to the UK MHRA for investigational RDEB therapy Ebstrocel. The company said faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027 subject to MHRA review.

Company

About INmune Bio, Inc.

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases. Its current product platforms include INKmune, a cell-based therapy designed to prime natural killer cells for oncology applications; INB03 and XPro1595, which target tumor necrosis factor-driven inflammation; and CORDstrom, a mesenchymal stem cell-based platform. The company’s programs are aimed at hematologic malignancies, solid tumors, chronic inflammation, and neurological conditions such as Alzheimer’s disease and treatment-resistant depression. INmune Bio Inc. works through a precision medicine approach, matching mechanisms of action to patient biology and clinical outcome measures. Headquartered in Boca Raton, Florida, the company operates in the biotechnology and immunology markets and focuses on advancing therapies that harness the body’s own immune response to fight disease.

CEO Mr. David J. Moss M.B.A. · 21 employees · United States · https://www.inmunebio.com